Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma

Bryukhovetskiy,Igor; Bryukhovetsky,Andrei; Khotimchenko,Yuri; Mischenko,Polina; Tolok,Elena; Khotimchenko,Rodion

doi:10.3892/mmr.2015.3754

Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma

Authors:
- Igor Bryukhovetskiy
- Andrei Bryukhovetsky
- Yuri Khotimchenko
- Polina Mischenko
- Elena Tolok
- Rodion Khotimchenko
View Affiliations

Affiliations: Laboratory of Molecular and Cellular Neurobiology, School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russian Federation, NeuroVita Clinic of Restorative Interventional Therapy and Neurology, Moscow 115478, Russian Federation, Laboratory of Pharmacology, A.V. Zhirmunski Institute of Marine Biology Far Eastern Branch Russian Academy of Science, Vladivostok 690041, Russian Federation
Published online on: May 7, 2015 https://doi.org/10.3892/mmr.2015.3754
Pages: 2828-2834

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GM) is an aggressive malignant tumor of the brain. The standard treatment of GM is surgical resection with consequent radio‑ and chemotherapy with temozolomide. The prognosis is unfavorable, with a survival time of 12‑14 months. The phenomenon of targeted migration to the tumor in the brain opens novel possibilities for the treatment of GM. Multipotent mesenchymal stromal cells (MMSCs) are a cell type with anti‑carcinogenic properties and can be used to optimize GM therapy. The aim of the present study was to investigate the effects of MMSC transplantation in the chemotherapy of a rat model of C6 glioma. A total of 130 animals were divided into a control group, a temozolomide group, MMSCs group and temozolomide + MMSCs group. The experiment was performed over 70 days, and a combination of molecular biology, surgical and neuroimaging techniques, as well as histological and physiological examinations was used. Tumor size was smallest in the temozolomide (115.76±16.25 mm3) and in temozolomide + MMSCs (114.74±5.54 mm3) groups, which was significantly smaller than the neoplastic node size in the control group (202.09±39.72 mm3) (P<0.05). The animals in the temozolomide + MMSCs group showed significantly higher survival rates in comparison with those in the control and temozolomide groups. The MMSCs migrated from the site of implantation to the neoplastic focus and interacted with glioma cells; however, the mechanism requires further research. In conclusion, MMSC transplantation combined with temozolomide treatment significantly extended the survival of experimental animals in comparison with those treated with temozolomide only.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	Hottinger AF, Stupp R and Homicsko K: Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer. 33:32–39. 2014. View Article : Google Scholar : PubMed/NCBI
3	Goffart N, Kroonen J and Rogister B: Glioblastoma-initiating cells: Relationship with neural stem cells and the micro-environment. Cancers (Basel). 5:1049–1071. 2013. View Article : Google Scholar
4	Pointer KB, Clark PA, Zorniak M, Alrfaei BM and Kuo JS: Glioblastoma cancer stem cells: Biomarker and therapeutic advances. Neurochem Int. 71:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ramirez YP, Weatherbee JL, Wheelhouse RT and Ross AH: Glioblastoma Multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel). 6:1475–1506. 2013. View Article : Google Scholar
6	Bryukhovetskyi IS, Bryukhovetskyi AS, Kumeiko VV, Mishenko PV and Khotimchenko YS: Stem cells in carcinogenesis of glioblastoma multiforme. Genes Cells. 8:13–19. 2013.In Russian.
7	Dong Y, Han Q, Zou Y, Deng Z, Lu X, Wang X, Zhang W, Jin H, Su J, Jiang T, et al: Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem. 370:89–102. 2012. View Article : Google Scholar : PubMed/NCBI
8	Mendiburu-Eliçabe M, Gil-Ranedo J and Izquierdo M: Efficacy of rapamycin against glioblastoma cancer stem cells. Clin Transl Oncol. 16:495–502. 2014. View Article : Google Scholar
9	Eimer S, Dugay F, Airiau K, Avril T, Quillien V, Belaud-Rotureau MA and Belloc F: Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neurooncol. 14:1441–1451. 2012.
10	Parney IF and Chang SM: Current chemotherapy for glioblastoma. Cancer J. 9:149–156. 2003. View Article : Google Scholar : PubMed/NCBI
11	Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M and Ohno K: Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg. 119:1145–1155. 2013. View Article : Google Scholar : PubMed/NCBI
12	Brower V: Early-stage progress on glioma vaccines. J Natl Cancer Inst. 103:1361–1362. 2011. View Article : Google Scholar : PubMed/NCBI
13	Rovere RK: Bevacizumab as secondline treatment of glioblastoma - worth the effort? Klin Onkol. 27:219–220. 2014.
14	Nagasawa T: CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (Berl). 92:433–439. 2014. View Article : Google Scholar
15	Bryukhovetskyi IS, Bryukhovetskyi AS, Mischenco PV and Khotimchenko YS: The role of systemic migration and homing mechanisms of stem cells in the development of malignant tumors of the central nervous system and the development of new cancer therapies. Russian Biotherapeutic J. 4:3–12. 2013.In Russian.
16	Rispoli R, Conti C, Celli P, Caroli E and Carletti S: Neural stem cells and glioblastoma. Neuroradiol J. 27:169–174. 2014. View Article : Google Scholar : PubMed/NCBI
17	Paltsev MA, Ivanov AA and Severin SE: Intercellular interactions. Medicine (Moscow). 2003, In Russian.
18	Bryukhovetskiy AS, Shevchenko VE, Chekhonin VP, Bryukhovetskiy IS, Kovalev SV, Baklaushev VP and Davydov MI: Comparative proteome mapping of tumor stem cells isolated from U87 glioblastoma, neural stem and multi-potent mesenchymal stromal cells of human: From cataloguing of cell proteins to novel paradigm of proteome-based cell therapy of tumors. Genes Cells. 8:85–92. 2013.
19	Grobben B, De Deyn PP and Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 310:257–270. 2002. View Article : Google Scholar : PubMed/NCBI
20	Swanson LW: Brain Maps: Structure of the Rat Brain. 2nd edition. Elsevier; Amsterdam: 1998
21	Pittenger MF: Mesenchymal stem cells from adult bone marrow. Methods Mol Biol. 449:27–44. 2008.PubMed/NCBI
22	Shen W, Hu JA and Zheng JS: Mechanism of temozolomide-induced antitumour effects on glioma cells. J Int Med Res. 42:164–172. 2014. View Article : Google Scholar
23	Tupper DE and Wallace RB: Utility of the neurological examination in rats. Acta Neurobiol Exp (Wars). 40:999–1003. 1980.
24	Victorov IV, Prass K and Dirnagl U: Improved selective, simple, and contrast staining of acidophilic neurons with vanadium acid fuchsin. Brain Res Brain Res Protoc. 5:135–139. 2000. View Article : Google Scholar : PubMed/NCBI
25	Shen G, Shen F, Shi Z, Liu W, Hu W, Zheng X, Wen L and Yang X: Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim. 44:280–289. 2008. View Article : Google Scholar : PubMed/NCBI
26	Barth RF and Kaur B: Rat brain tumor models in experimental neurooncology: The C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 94:299–312. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hirst TC, Vesterinen HM, Sena ES, Egan KJ, Macleod MR and Whittle IR: Systematic review and meta-analysis of temozolomide in animal models of glioma: Was clinical efficacy predicted? Br J Cancer. 108:64–71. 2013. View Article : Google Scholar : PubMed/NCBI
28	Steinbach JP, Wolburg H, Klumpp A, Probst H and Weller M: Hypoxia-induced cell death in human malignant glioma cells: Energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ. 10:823–832. 2003. View Article : Google Scholar : PubMed/NCBI
29	Yang L, Lin C, Wang L, Guo H and Wang X: Hypoxia and hypocia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res. 318:2417–2426. 2012. View Article : Google Scholar : PubMed/NCBI
30	Zhang MH, Hu YD, Xu Y, Xiao Y, Luo Y, Song AC and Zhou J: Human mesenchymal stem cells enhance autophagy of lung carcinoma cells against apoptosis during serum deprivation. Int J Oncol. 42:1390–1398. 2013.PubMed/NCBI
31	Hou L, Wang X, Zhou Y, Ma H, Wang Z, He J, Hu H, Guan W and Ma Y: Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells. Tumour Biol. 35:1239–1250. 2014. View Article : Google Scholar
32	Li Q, Wijesekera O, Salas SJ, Wang JY, Zhu M, Aprhys C, Chaichana KL, Chesler DA, Zhang H, Smith CL, et al: Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival. Clin Cancer Res. 20:2375–2387. 2014. View Article : Google Scholar : PubMed/NCBI
33	Baraniak PR and McDevitt TC: Stem cell paracrine actions and tissue regeneration. Regen Med. 5:121–143. 2010. View Article : Google Scholar :
34	Bryukhovetskiy A, Bryukhovetskiy I, Chekhonin V and Baklaushev V: Experimental cytoregulatory therapy of brain glial tumors with cell system of hematopoietic precursors epigenetically reprogrammed of apoptosis induction: Victory in vitro and failure in vivo. J Neurol. 257(Suppl 1): S152–S153. 2010.
35	Liu J, Zhang Y, Bai L, Cui X and Zhu J: Rat bone marrow mesenchymal stem cells undergo malignant transformation via indirect co-cultured with tumour cells. Cell Biochem Funct. 30:650–656. 2012. View Article : Google Scholar : PubMed/NCBI